加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) (Stock Code 股份代號: 1167)

1 March 2024

Dear registered shareholder(s),

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, Jacobio Pharmaceuticals Group Co., Ltd. (the "Company") is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"), which mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form. No printed copies of Corporate Communications will be mailed to you except by request.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.jacobiopharma.com and the HKEXnews website at www.hkexnews.hk in place of printed copies. You need to proactively check the Company's website and the HKEXnews website to keep up with the publication of Corporate Communications.

Solicitation of electronic contact details

To ensure timely receipt of the Actionable Corporate Communications^(Note), the Company recommends you provide your email address by scanning your personalized QR code printed on the reply form (the "**Reply Form**") on the reverse side. Alternatively, you may sign and return the Reply Form to the Company's Hong Kong share registrar (the "**Share Registrar**"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Share Registrar, the Company will send the Actionable Corporate Communications^(Note) in printed form in the future.

We encourage you to access all Corporate Communications in electronic form on the Company's website. If you want to receive the Corporate Communications in printed form, please complete and return the Reply Form on the reverse side to the Share Registrar or send an email to jacobio.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter. Further request in writing will be required if a shareholder prefers to continue receiving hard copies of future Corporate Communications.

Should you have any queries relating to this letter, please contact the Share Registrar at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

Yours faithfully,
By order of the Board

JACOBIO PHARMACEUTICALS GROUP CO., LTD.

Yinxiang WANG

Chairman

Note: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holders.

各位登記股東:

以電子方式發佈公司通訊之安排

據自 2023 年 12 月 31 日起生效的擴大無紙化上市機制及以電子方式發佈公司通訊規定下香港聯合交易所有限公司證券上市規則(「**上市規則**」)第 2.07A 條,加科思藥業集團有限公司(「**公司**」)謹此通知 閣下,公司已採用以電子方式發佈公司通訊(「**公司通訊**」)之安排,該公司通訊是指公司為向其任何證券持有人提供資訊或提醒其採取行動而發佈或將要發佈的任何文件,包括但不限於(a) 董事會報告、年度帳目連同核數師報告以及(如適用)財務摘要報告; (b) 中期報告及其中期摘要報告(如適用); (c) 會議通知; (d) 上市文件; (e) 通函和 (f) 代表委任表格。除非您有特別要求,否則公司不會向您郵寄印刷版的公司通訊。

請注意,所有未來公司通訊的英文版和中文版將以電子方式在本公司網站 <u>www.jacobiopharma.com</u> 和披露易網站 <u>www.hkexnews.hk</u>上提供,以代替印刷本。 **閣**下需要主動查看公司網站和披露易網站以留意公司通訊的發佈。

徵集電子聯絡資料

為確保及時收到可供採取行動的公司通訊^(網註),公司建議 閣下透過掃描本函背頁之回條(「**回條**」)上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。或者, 閣下也可以簽署回條並交回公司的香港股份過戶登記處(「**股份過戶處**」)香港中央證券登記有限公司,地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

如果公司沒有收到 閣下的有效電子郵件地址,直至股份過戶處收到 閣下有效的電子郵件地址前,本公司未來將以印刷本形式發送可供採取行動的公司通訊(開始)。

我們鼓勵您在公司網站上閱讀所有的電子公司通訊。若 閣下希望收取公司通訊之印刷版,請填妥本函背頁之回條並交回股份過戶處,或發送電子郵件至 jacobio.ecom@computershare.com.hk, 並註明 閣下的姓名、地址以及收取公司通訊印刷版的要求。 請注意,收取未來公司通訊印刷版之指示由收悉 閣下指 示當日起計一年內有效,此後將過期。 如果股東希望繼續接收未來的公司通訊的印刷版,將需要提交進一步的書面請求。

如 閣下對本函件有任何疑問,請於辦公時間星期一至五(香港公眾假期除外)上午9時正至下午6時正(香港時間)其間致電股份過戶處(852)2862 8688 查詢。

承董事會命

加科思藥業集團有限公司

董事長 **王印祥** 謹啟

2024年3月1日

REPLY	FORM	回條

香港中央證券登記有限公司 (「股份過戶處」)

17M Floor, Hopewell Centre

183 Oueen's Road East, Wan Chai, Hong Kong

香港灣仔皇后大道東 183 號 合和中心 17M 樓

(Please **choose ONLY ONE** of the options below) (請從以下選項中**只選擇其中一項**)

Personalized QR Code 專屬二維碼

Option 1: Provide your email address for receipt of future Actionable Corporate Communications(Note 3) of the Company via electronic dissemination by scanning

your personalized QR code

選項1:

閣下專屬二維碼提供 閣下之電子郵件地址,以接收公司通過電子方式 發佈的可供採取行動的未來公司通訊^(附註3)

You are **NOT required** to return this Reply Form if you choose Option 1. 如選擇了選項1 見閣下無須交回本回條。

Option 2:I/we hereby provide my/our email address in writing for receipt of future Actionable Corporate Communications (Note 3) of the following listed company (the "Company") via electronic dissemination.選項 2本人/吾等現以書面提供本人/吾等之電子郵件地址・以確保收到以下上市公司(「公司」)通過電子方式發佈的可供採取行動的未來公司通訊(附註3)					
Name of Securities holder(s) 證券持有人姓名: Name of the listed company 上市公司名稱: JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加科思藥業集團有限公司					
Email address 電郵地址: (Note 3 / 附註 3)					
Ontion 3: I/we hereby request for receipt of Corporate Communications* in printed form (Please mark "\sqrt{"}" in the below box if applicable)					

Option 3:	I/we hereby request for receipt of Corporate Communications* in printed form (Please mark "✓" in the below box if applicable)			
選項3:	本人/吾等現要求收取公司通訊 [*] 印刷版 (如適用・請在以下方格內劃上「✓」號)			
receive future Corporate Communications* in printed copy and noted that this instruction is valid only for one year starting from the receipt date of instruction. (Note 5)				

Signature(s): ^(Note 1)	Contact number:	Date:
簽名: ^(附註 1)	聯絡電話號碼:	日期:

- otes 附註:
 Please complete all your details clearly. If your shares are held in joint names, all of the joint shareholders should jointly sign this Reply Form in order to be valid.
 請清楚填妥 圖下之所有資料。如圖聯名股東、則本回條須由所有聯名股東聯合簽署、方為有效。
 Any Reply Form with no signature or otherwise incorrectly completed will be void.
 任何回條若未有養著或生食地方面填露入证確,則不可能稱為自然表情疾患。
 If the Company does not receive a functional email address in your reply, you will be unable to receive notifications regarding the publication of Corporate Communications*. Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holders.
 如公司沒有收到 圖下的有效電子郵件地址、 圖下將無法收到有關發佈公司通訊。的通知。可供採取行動的公司通訊指任何涉及要求發行人的證券特有人指示其疑如何行使其有關 證券特有人的權利或作出選擇的公司通訊 司補訊。
- 司題語。
 4. If you provide more than one email address by QR code, email, reply form and/or other means, only the latest one email address provided will be registered.
 如 蘭下遜姆二維碼、電影、回線及/或具他方式提供多於、回的電子影件地址、只有 萬下臺德提供的電子影件地址將會被用於登記。
 5. If you mark "》" in the box in Option 3, no email address will be registered and only Corporate Communications* in printed form will be received.
 如 屬下在獎頂 3 方格內劃上 「夕」號、將不會有電子郵件地址被登記。只有公司通訊*約印刷版會被收取。
 6. For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form.
 為免存疑。在本回線上的任何額外指示、公司將不予處理。

- Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to the annual report, interim report, notice of meeting, circular and proxy form.

 解析 公司權利力指令司已發起職养發出政策上發出政策人對性政策上行動等的持有人參照或採取行動的任何文件,其中包括但不限於年報、中期報告、會議議告、通過及代表委任表格。

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

- "Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO").
 本聲明中所指的「個人資料,與香港法例第486 章(個人資料、穩陽)條例)(「《私陽條例》」)(「個人資料」的涵義相同。
 Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to, the Company's electronic dissemination of Corporate Communications and to liaise with you on other matter relating to your holdings in the Company. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction and/or request as stated in this Reply Form.

 圖下於本回條所提供的個人資料將用於包括但不規於有關公司以電子方式發佈公司通訊及就 閣下持有的公司證券有關的其他事宜上與 閣下聯絡。閣下是自顧向本公司提供個人資料。若閣下未能提供足夠資料。
- You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal I should be in writing, by mail to the Hong Kong Privacy Officer of the Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or by email ivacyOfficer@computershare.com.hk. 下有權根據《私隱條例》的條文查閱及/或修改 間下的個人資料。任何該等查閱及/或修改個人資料的要求均須以書面方式郵寄至股份過戶處(地址為香港灣仔皇后大道東 183 號合和中心 17M 樓)向香港私隱主

任提出·或發送電郵至 PrivacyOfficer@computershare.com.hk

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited 香港中央證券登記有限公司 Freepost No. 簡便回郵號碼:37 Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us.

No postage is necessary if posted in Hong Kong.

閣下寄回此回條時·請將郵寄標籤剪貼於信封上 如在本港投寄· 閣下無需支付郵費或貼上郵票。